1) Bray F, Ferlay J, Soerjomataram Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.
2) Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology. 2003;61:14–24.
3) Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D’amico risk classification of prostate cancer. Urology. 2007;70:931–5.
4) Sanguineti G, Cavey ML, Endres EJ, Brandon GG, Bayouth JE. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer? Int J Radiat Oncol Biol Phys. 2006, 64:151–160.
5) Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1–T3 adenocarcinoma of the prostate. Urology. 2000; 55(1):85–90.
6) Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA. Higher than standard radiation doses (72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 46(3):567–574.
7) Kupelian PA, Buchsbaum JC, Reddy CA, Klein EA. Radiation dose response in patients with favorable localized prostate cancer (stage T1–T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or =10). Int J Radiat Oncol Biol Phys. 2001; 50(3): 621–625.
8) Akakura K, Tsujii H, Morita S, Tsuji H, Yagishita T, Isaka S, Ito H, Akaza H, Hata M, Fujime M, Harada M, Shimazaki J. Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 2004;58(3):252–8.
9) Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka T, Furusawa Y, Ando K, Suzuki M, Soga F, Kawachi K. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:201–10.
10) Kanai T, Matsufuji N, Miyamoto T, Mizoe J, Kamada T, Tsuji H, Kato H, Baba M, Tsujii H. Examination of GyE system for HIMAC carbon therapy. Int J Radiat Oncol Biol Phys. 2006;64:650–6.
11) Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–64.
12) Ishikawa H, Tsuji H, Kamada T, Akakura K, Suzuki H, Shimazaki J, Tsujii H. Carbon-ion radiation therapy for prostate cancer. Int J Urol. 2012 Apr;19(4):296-305.
13) Nomiya T, Tsuji H, Kawamura H, Ohno T, Toyama S, Shioyama Y, Nakayama Y, Nemoto K, Tsujii H, Kamada T. A multi-institutional analysis of prospective studies of carbon-ion radiotherapy for prostate cancer: A report from the Japan Carbon-ion Radiation Oncology Study Group (J-CROS). Radiother Oncol. 2016 Nov;121(2):288-293.
14) Nakayama Y, Minohara S, Nonaka T, Nomiya T, Kusano Y, Takeshita E, Mizoguchi N, Hagiwara Y. The Ion-Beam Radiation Oncology Center in Kanagawa (i-ROCK) Carbon Ion Facility at the Kanagawa Cancer Center. Int J Part Ther. 2016 Winter;2(3):478-480.
15) Tsujii H, Kamada T, Shirai T, Noda K, Tsuji H, Karasawa K. Carbon-Ion Radiotherapy; Springer: Japan, 2014; pp. 53-64
16) Minohara S, Fukuda S, Kanematsu N, Takei Y, Furukawa T, Inaniwa T, Matsufuji N, Mori S, Noda K. Recent innovations in carbon-ion radiotherapy. J Radiat Res. 2010;51(4):385-92.
17) Ute L. Ion Beam Therapy; Springer: Heidelbelg, Germany, 2012; pp45-59
18) Weber U, Becher W, Kraft G. Depth scanning for a conformal ion beam treatment of deep seated tumours. Phys Med Biol. 2000 Dec;45(12):3627-41.
19) Pedroni E, Bacher R, Blattmann H, Böhringer T, Coray A, Lomax A, Lin S, Munkel G, Scheib S, Schneider U. The 200-MeV proton therapy project at the Paul Scherrer Institute: conceptual design and practical realization. Med Phys. 1995 Jan;22(1):37-53.
20) Chu WT, Ludewigt BA, Renner TR. Instrumentation for treatment of cancer using proton and light-ion beams. Rev Sci Instrum. 1993;64:2055-2122
21) D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11):969–974.
22) Kawamura H, Kubo N, Sato H, Mizukami T, Katoh H, Ishikawa H, Ohno T, Matsui H, Ito K, Suzuki K, Nakano T; Group for Genitourinary Tumors at Gunma University Heavy Ion Medical Center. Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study "GUNMA0702". BMC Cancer. 2020 Jan 30;20(1):75.
23) Kasuya G, Ishikawa H, Tsuji H, Haruyama Y, Kobashi G, Ebner DK, Akakura K, Suzuki H, Ichikawa T, Shimazaki J, Makishima H, Nomiya T, Kamada T, Tsujii H; Working Group for Genitourinary Tumors. Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy. Cancer Sci. 2017 Dec;108(12):2422-2429.
24) Tsuji H, Yanagi T, Ishikawa H, Kamada T, Mizoe JE, Kanai T, Morita S, Tsujii H. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys. 2005; 63: 1153–60.
25) Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe JE, Kanai T, Morita S, Wakatsuki M, Shimazaki J, Tsujii H. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol. 2006; 81: 57–64.
26) Roach M 3rd, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radio therapy with clinically localized prostate cancer:recommendations of the RTOG- ASTRO Phoenix Consensus Conference. Int J Radiation Oncol Biol Phys. 2006; 65: 965- 74.
27) Hanks GE. Conformal radiotherapy for prostate cancer. Ann Med. 2000 Feb;32(1):57-63.
28) Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 62(5): 1297–1308.
29) Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105.
30) Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85(11): 2460–2468.
31) Sveistrup J, af Rosenschöld PM, Deasy JO, Oh JH, Pommer T, Petersen PM, Engelholm SA. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol 2014;9(1):44.
32) Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler HM. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys. 2013; 87(5): 932–938.
33) Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1424-30.
34) Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, Rossi CJ. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03–12. Int J Radiat Oncol Biol Phys. 2011;81:1005–9.
35) Iwata H, Ishikawa H, Takagi M, Okimoto T, Murayama S, Akimoto T, Wada H, Arimura T, Sato Y, Araya M, Mizoe JE, Gosho M, Nakamura K, Shirato H, Sakurai H. Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med. 2018 Mar;7(3):677-689.
36) Ishikawa H, Tsuji H, Kamada T, Hirasawa N, Yanagi T, Mizoe JE, Akakura K, Suzuki H, Shimazaki J, Tsujii H. Risk factors of late rectal bleeding after carbon-ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4)
37) Byrne K, Hruby G, Kneebone A, Whalley D, Guo L, McCloud P, Eade T. Late genitourinary toxicity outcomes in 300 prostate cancer patients treated with dose-escalated image-guided intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2017 Sep;29(9):617-625.
38) Kalakota K, Liauw SL. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Urology. 2013 Jun;81(6):1196-201.
39) Ishikawa H, Tsuji H, Kamada T, Hirasawa N, Yanagi T, Mizoe JE, Akakura K, Suzuki H, Shimazaki J, Nakano T, Tsujii H. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon-ion radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):78-84.
40) Nomiya T, Tsuji H, Toyama S, Maruyama K, Nemoto K, Tsujii H, Kamada T. Management of high-risk prostate cancer: radiation therapy and hormonal therapy. Cancer Treat Rev. 2013 Dec;39(8):872-878.
41) Hausterman K, Fowler JF. A comment on proliferation rates in human prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 48(1):303.
42) Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016; 17(4):464–474.
43) Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016; 17(8):1047–1060.
44) Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, Bauman GS, Bahary JP, Ahmed S, Cheung P, Tai KH, Wu JS, Parliament MB, Tsakiridis T, Corbett TB, Tang C, Dayes IS, Warde P, Craig TK, Julian JA, Levine MN.Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017; 35(17):1884–1890.
45) Takakusagi Y, Kawamura H, Okamoto M, Kaminuma T, Kubo N, Mizukami T, Sato H, Onishi M, Ohtake N, Sekihara T, Nakano T. Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study. PLoS One. 2019 Feb 26;14(2):e0211370.
46) Zilli T, Franzese C, Bottero M, Giaj-Levra N, Förster R, Zwahlen D, Koutsouvelis N, Bertaut A, Blanc J, Roberto D'agostino G, Alongi F, Guckenberger M, Scorsetti M, Miralbell R. Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiother Oncol. 2019 Oct;139:83-86.
47) Alongi F, Fiorentino A, De Bari B. SBRT and extreme hypofractionation: A new era in prostate cancer treatments? Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):411-6.
48) Nicosia L, Mazzola R, Rigo M, Figlia V, Giaj-Levra N, Napoli G, Ricchetti F, Corradini S, Ruggieri R, Alongi F. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. J Cancer Res Clin Oncol. 2019 Oct;145(10):2547-2554.
49) Burchardt W, Skowronek J. Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer. J Contemp Brachytherapy. 2018 Feb;10(1):1-9.
50) Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007; 69: 426-433.
51) Caloglu M, Ciezki J. Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon. Urology 2009; 74: 1183-1190.